Biotechnology sector posts record turnover and R&D investments

In 2021, turnover and spending on research and development (R&D) in the German biotechnology sector soared. With a 279 percent increase in turnover (€26.32 billion) and a 54 percent increase in R&D investments (€3.84 billion), new records were set. The main reason for the new records is the success of vaccine developer BioNTech, but the company CureVac is also making a significant contribution to the growth in R&D investment with its vaccine research. This is the result of a survey of 750 private biotech companies published today by the biotechnology industry association BIO Deutschland, as well as data from the 24 German listed companies. At 16 percent, the increase in jobs is also large, although here the increase is similar for both private (13 percent) and listed (20 percent) companies, in contrast to turnover and R&D investment. However, the number of companies in Germany is stagnating, as it did in 2020.

The full text of this press release is available for you at www.biodeutschland.org/en/press-releases/...